An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum

Phase 4

• Conditions: Asperger's Disorder; Autism; PDD; Autistic Disorder; Pervasive Developmental Disorder
• Interventions: Drug: Gammaplex 5%

• Registration Number: NCT02199925
• Lead Sponsor: Isaac Melamed

Brief Summary

If autism is the consequence of a chronic inflammatory process preventing the infant brain from forming the proper neural connections, then treatment that reduces inflammation might have a positive impact on autism. IGIV treatment has been known to suppress inflammation and has been used in the treatment of inflammatory conditions and autoimmune diseases.

Detailed Description

We have come to believe that an immature immune system with abnormal signaling and altered apoptotic pathways may result in a process of neuroinflammation with a clinical presentation of Autism Spectrum Disorder. If Autism Spectrum Disorders are the consequence of a chronic inflammatory process that prevents the infant brain from forming the proper neural connections, then treatment that reduces inflammation might have a positive impact on autism. We believe that there is a correlation between immunological abnormalities and the development of the autism.

Study Timeline

• Study Start: 2013-06
• Study First Submitted: 2014-07-21
• Study First Submitted QC: 2014-07-23
• Study First Posted: 2014-07-25
• Status Verified: 2015-03
• Primary Completion: 2015-04
• Last Update Submitted: 2015-04-15
• Last Update Posted: 2015-04-16
• Study Completion: 2015-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• The subject is between the ages of or equal to 4 and 12 years of age, of either gender, and belonging to any ethnic group.
• The subject has a diagnosis, for a minimum of 6 months prior to screening, of either autistic disorder, Asperger disorder, or pervasive developmental disorder (PDD).
• Normal physical test results.
• Immunological lab results showing reduced levels of activated CD40L or abnormal lymphocyte stimulation, or T or B cell dysfunction (hypgammaglobulinemia, primary immunodeficiency (PIDD), or common variable immune deficiency (CVID).

Exclusion Criteria

• A diagnosis of isolated IGA deficiency
• Allergic reactions to blood products

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Gammaplex 5% IGIV	Gammaplex 5%	Gammaplex 5% IGIV administered intravenously

Primary Outcome Measures

Name	Time	Method
The primary objective is to assess the efficacy of Gammaplex as an immunomodulatory therapy in autistic children with evidence of immune dysfunction.	1 year	The primary endpoint is disease improvement, as evidenced by standardized test measures across 3 intervals: screening for baseline measurements, visit 5, and end of study visit measurements. Primary efficacy variables will be measured using the following standardized tests; 1. Caregiver Scales (SRS, CCC-2, ABC); 2. CGI-S and CGI - I; 3. PPVT; 4. ADOS

Secondary Outcome Measures

Name	Time	Method
The modulatory effect of IVIG on neuroinflammation will be assessed by laboratory measurements which we believe are indicative of immune dysregulation.	1 year

Trial Locations

Locations (1)

IMMUNOe International Research Centers; 🇺🇸 Centennial, Colorado, United States